VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial

Verastem Executive Compensation (FY25)

VSTM · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Daniel Paterson
Latest say-on-pay support
=
May 21, 2026
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing

The Verastem brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
Data as of November 5, 2026Latest filing (8-K): May 26, 2026
10 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Verastem brief$500Get the executive brief
Velarion Intel, one year, every company
200 figures on this page: 192 cited to the filing that reported them, 8 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Daniel Paterson: $2,536,767 → $2,349,975 (7.4% lower)
Say-on-pay support: 82.9% → 95.3% (12.4 points higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Verastem's chief executive and what were they paid?
Total compensation for Daniel Paterson, President and Chief Executive Officer, came to $2,349,975 in fiscal 2025. Paterson's total moved 7.4% lower from the $2,536,767 reported for fiscal 2024.
What was Verastem's say-on-pay result?
Shareholders supported the say-on-pay proposal with 95.3% of votes cast for or against in favor at the meeting held May 21, 2026 for fiscal 2025.
Which companies are in Verastem's peer group?
The disclosed peer group includes Acrivon Therapeutics, Inc., Actinium Pharmaceuticals, Inc., Aura Biosciences, Inc., Cardiff Oncology, Inc. and Celcuity Inc., among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Brian Stuglik
Former Chief Executive Officer
◇———◇—◇◇
Daniel Paterson
President and Chief Executive Officer
◇———◇—◇◇
Daniel Calkins
Chief Financial Officer
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Daniel Paterson
President and Chief Executive Officer
◇—◇◇◇—◇◇
Brian Stuglik
Former Chief Executive Officer
Departed during or after this year
◇——◇◇—◇◇
Daniel Calkins
Chief Financial Officer
◇——◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Daniel Paterson
President and Chief Executive Officer
◇—◇◇◇—◇◇
Daniel Calkins
Chief Financial Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Daniel Paterson
President and Chief Executive Officer
◇—◇—◇—◇◇
Matthew Ros
Former Chief Operating Officer
Departed during or after this year
◇—◇—◇—◇◇
Daniel Calkins
Chief Financial Officer
◇—◇—◇—◇◇
Michael Kauffman
President of Development
◇—◇◇——◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Daniel CalkinsRSU◇——◇———
Daniel CalkinsPSU◇——◇———
Daniel PatersonRSU◇——◇———
Daniel PatersonPSU◇——◇———
Matthew RosPSU◇——◇———
Matthew RosRSU◇——◇———
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Daniel PatersonRSU◇◇——
Option◇—◇3/11/2034
PSU◇◇——
Option◇—◇1/27/2033
Option◇—◇8/2/2033
RSU◇◇——
Option◇—◇3/11/2034
Option◇—◇1/3/2029
Daniel CalkinsRSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇10/24/2033
Option◇—◇1/27/2033
Option◇—◇3/11/2034
Option◇—◇10/3/2032
Option◇—◇3/11/2034
RSU◇◇——
Michael KauffmanOption◇—◇3/11/2034
Option◇—◇5/22/2035
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Daniel Calkins
Chief Financial Officer · Employment agreement
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Daniel Paterson
President and Chief Executive Officer · Employment agreement
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Michael Kauffman
President of Development · Employment agreement
Severance multiple◇
Severance base◇
Change-in-control multiple◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Michael Kauffman, M.D., Ph.D
◇◇◇———◇
Eric Rowinsky, M.D
◇◇◇——◇◇
Anil Kapur
◇◇◇———◇
Michelle Robertson
◇◇◇———◇
Brian Stuglik
◇◇◇———◇
John Johnson
Lead independent director
◇◇◇———◇
Karin Tollefson
◇◇◇———◇
Paul Bunn, M.D
◇◇◇———◇
Robert Gagnon
◇◇◇———◇
Michael P. Bailey and Daniel Paterson served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Acrivon Therapeutics, Inc. ACRV
  • Actinium Pharmaceuticals, Inc. ATNM
  • Aura Biosciences, Inc. AURA
  • Cardiff Oncology, Inc. CRDF
  • Celcuity Inc. CELC
  • Cogent Biosciences, Inc. COGT
  • Compass Therapeutics, Inc. CMPX
  • Cullinan Oncology, Inc. CGEM
  • iTeos Therapeutics, Inc. ITOS
  • Kura Oncology, Inc. KURA
  • Leap Therapeutics, Inc. symbol not shown
  • MEI Pharma, Inc. MEIP
  • Olema Pharmaceuticals, Inc. OLMA
  • Scholar Rock Holding Corporation SRRK
  • Syros Pharmaceuticals, Inc. SYRS
  • Terns Pharmaceuticals, Inc. TERN

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 21, 2026=◇◇◇
2024May 22, 2025=◇◇◇
2023May 23, 2024=◇◇◇
2022May 15, 2023=◇◇◇
2021May 12, 2022=◇◇◇
2020May 18, 2021=◇◇◇
2019May 19, 2020=◇◇◇
2018May 14, 2019=◇◇◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Daniel Paterson (President and Chief Executive Officer), FY2025 total compensation $2,349,975 (base salary $674,000) [exec_comp, SEC accession 0001104659-26-041506, filed 2026-04-09]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Verastem files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Verastem disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Verastem sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Verastem's disclosed peer group is defensible, who names Verastem back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
200 figures on this page: 192 cited to the filing that reported them, 8 calculated from figures it prints.
192 cited to the filing
8 calculated from the filing

Documents cited

  1. 0001104659-26-066026
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  2. 0001104659-26-041506
    Proxy severance section
  3. 0001104659-25-052220
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  4. 0001104659-24-064781
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  5. 0001558370-24-005017
  6. 0001558370-23-010004
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  7. 0001558370-22-008974
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  8. 0001558370-21-007577
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  9. 0001104659-20-064756
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  10. 0001558370-19-005181
    Item 5.07. Submission of Matters to a Vote of Security Holders.
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Verastem executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/VSTM (accessed 2026).
Short form: data: Velarion

The Verastem brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
10 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Verastem and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Verastem discloses

The companies named in VSTM's own disclosed peer group.

Acrivon Therapeutics, Inc.Actinium Pharmaceuticals, Inc.Aura Biosciences, Inc.Cardiff Oncology, Inc.Celcuity Inc.Cogent Biosciences, Inc.Compass Therapeutics, Inc.Cullinan Oncology, Inc.iTeos Therapeutics, Inc.Kura Oncology, Inc.Olema Pharmaceuticals, Inc.Scholar Rock Holding CorporationSyros Pharmaceuticals, Inc.Terns Pharmaceuticals, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy